NFA
PTGX icon

Nationwide Fund Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Nationwide Fund Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,345
Closed -$77K – 1593
2017
Q3 		$77K Hold
4,345
– – ﹤0.01% 2979
2017
Q2 		$49K Hold
4,345
– – ﹤0.01% 3056
2017
Q1 		$56K Sell
4,345
-589
-12% -$9.49K ﹤0.01% 2967
2016
Q4 		$108K Buy
4,934
+2,833
+135% +$63.2K ﹤0.01% 2854
2016
Q3 		$44K Buy
+2,101
New +$28.7K ﹤0.01% 3062

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Nationwide Fund Advisors's PTGX Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Protagonist Therapeutics (PTGX) in Q4 2017, closing a stake of 4,345 shares — an estimated $77K sold.

Nationwide Fund Advisors first reported a position in PTGX in Q3 2016 and held it in 5 quarters. The position peaked at $108K in Q4 2016. 66 funds tracked by Wall St. Rank hold PTGX as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Protagonist Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 4,345 Protagonist Therapeutics shares in Q4 2017, an estimated $77K.
  • Nationwide Fund Advisors first reported a position in Protagonist Therapeutics in Q3 2016 and held it in 5 quarters.
  • Nationwide Fund Advisors's Protagonist Therapeutics position peaked at $108K in Q4 2016.
  • 66 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.